239 related articles for article (PubMed ID: 22233582)
1. Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.
Wennier ST; Liu J; Li S; Rahman MM; Mona M; McFadden G
Mol Ther; 2012 Apr; 20(4):759-68. PubMed ID: 22233582
[TBL] [Abstract][Full Text] [Related]
2. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Bhattacharyya M; Francis J; Eddouadi A; Lemoine NR; Halldén G
Cancer Gene Ther; 2011 Oct; 18(10):734-43. PubMed ID: 21836633
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Myxoma Virus Expressing Walleye Dermal Sarcoma Virus orfC Is Attenuated in Rabbits.
Ashton LV; Quackenbush SL; Castle J; Wilson G; McCoy J; Jordan M; MacNeill AL
Viruses; 2020 May; 12(5):. PubMed ID: 32397134
[TBL] [Abstract][Full Text] [Related]
4. Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer.
Watanabe I; Kasuya H; Nomura N; Shikano T; Shirota T; Kanazumi N; Takeda S; Nomoto S; Sugimoto H; Nakao A
Cancer Chemother Pharmacol; 2008 Apr; 61(5):875-82. PubMed ID: 17726607
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer.
Chen W; Fan W; Ru G; Huang F; Lu X; Zhang X; Mou X; Wang S
Oncol Rep; 2019 Jan; 41(1):67-76. PubMed ID: 30365143
[TBL] [Abstract][Full Text] [Related]
6. Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells.
Han Z; Lee S; Je S; Eom CY; Choi HJ; Song JJ; Kim JH
Apoptosis; 2016 Mar; 21(3):351-64. PubMed ID: 26677013
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
Leitner S; Sweeney K; Oberg D; Davies D; Miranda E; Lemoine NR; Halldén G
Clin Cancer Res; 2009 Mar; 15(5):1730-40. PubMed ID: 19223497
[TBL] [Abstract][Full Text] [Related]
8. Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells.
Rahman MM; Bagdassarian E; Ali MAM; McFadden G
Sci Rep; 2017 Nov; 7(1):15710. PubMed ID: 29146961
[TBL] [Abstract][Full Text] [Related]
9. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.
McKenzie BA; Zemp FJ; Pisklakova A; Narendran A; McFadden G; Lun X; Kenchappa RS; Kurz EU; Forsyth PA
Neuro Oncol; 2015 Aug; 17(8):1086-94. PubMed ID: 25605818
[TBL] [Abstract][Full Text] [Related]
10. Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer.
Kangasniemi L; Parviainen S; Pisto T; Koskinen M; Jokinen M; Kiviluoto T; Cerullo V; Jalonen H; Koski A; Kangasniemi A; Kanerva A; Pesonen S; Hemminki A
Int J Cancer; 2012 Jul; 131(1):253-63. PubMed ID: 21834073
[TBL] [Abstract][Full Text] [Related]
11. Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.
Zemp FJ; McKenzie BA; Lun X; Reilly KM; McFadden G; Yong VW; Forsyth PA
Cancer Res; 2014 Dec; 74(24):7260-73. PubMed ID: 25336188
[TBL] [Abstract][Full Text] [Related]
12. Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer.
Rahman MM; van Oosterom F; Enow JA; Hossain M; Gutierrez-Jensen AD; Cashen M; Everts A; Lowe K; Kilbourne J; Daggett-Vondras J; Karr TL; McFadden G
Cancer Res Commun; 2023 Jun; 3(6):952-968. PubMed ID: 37377603
[TBL] [Abstract][Full Text] [Related]
13. RNA Helicase A/DHX9 Forms Unique Cytoplasmic Antiviral Granules That Restrict Oncolytic Myxoma Virus Replication in Human Cancer Cells.
Rahman MM; Gutierrez-Jensen AD; Glenn HL; Abrantes M; Moussatche N; McFadden G
J Virol; 2021 Jun; 95(14):e0015121. PubMed ID: 33952639
[TBL] [Abstract][Full Text] [Related]
14. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV.
Angelova AL; Aprahamian M; Grekova SP; Hajri A; Leuchs B; Giese NA; Dinsart C; Herrmann A; Balboni G; Rommelaere J; Raykov Z
Clin Cancer Res; 2009 Jan; 15(2):511-9. PubMed ID: 19147756
[TBL] [Abstract][Full Text] [Related]
15. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.
Lun X; Alain T; Zemp FJ; Zhou H; Rahman MM; Hamilton MG; McFadden G; Bell J; Senger DL; Forsyth PA
Cancer Res; 2010 Jan; 70(2):598-608. PubMed ID: 20068158
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic myxoma virus: the path to clinic.
Chan WM; Rahman MM; McFadden G
Vaccine; 2013 Sep; 31(39):4252-8. PubMed ID: 23726825
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer.
Jung KH; Choi IK; Lee HS; Yan HH; Son MK; Ahn HM; Hong J; Yun CO; Hong SS
Cancer Lett; 2017 Jun; 396():155-166. PubMed ID: 28315430
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
Kellish P; Shabashvili D; Rahman MM; Nawab A; Guijarro MV; Zhang M; Cao C; Moussatche N; Boyle T; Antonia S; Reinhard M; Hartzell C; Jantz M; Mehta HJ; McFadden G; Kaye FJ; Zajac-Kaye M
J Clin Invest; 2019 Apr; 129(6):2279-2292. PubMed ID: 31033480
[TBL] [Abstract][Full Text] [Related]
19. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.
Zemp FJ; Lun X; McKenzie BA; Zhou H; Maxwell L; Sun B; Kelly JJ; Stechishin O; Luchman A; Weiss S; Cairncross JG; Hamilton MG; Rabinovich BA; Rahman MM; Mohamed MR; Smallwood S; Senger DL; Bell J; McFadden G; Forsyth PA
Neuro Oncol; 2013 Jul; 15(7):904-20. PubMed ID: 23585629
[TBL] [Abstract][Full Text] [Related]
20. Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.
Correa RJ; Komar M; Tong JG; Sivapragasam M; Rahman MM; McFadden G; Dimattia GE; Shepherd TG
Gynecol Oncol; 2012 May; 125(2):441-50. PubMed ID: 22306204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
